Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for all European Cotellic: Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany
Information about Cotellic (Cobimetinib)
Cotellic is a prescription medication used in the treatment of certain types of cancer. Its active ingredient, cobimetinib, is a targeted therapy that inhibits specific proteins involved in cancer cell growth and proliferation. Cotellic is often used in combination with other cancer treatments to improve efficacy and outcomes.
Product Highlights
Cotellic specifically targets and inhibits MEK1 and MEK2 proteins, which are part of the MAPK/ERK pathway involved in tumor growth.
Typically used in combination with vemurafenib for the treatment of melanoma with specific genetic mutations, enhancing overall treatment effectiveness.
Primarily used to treat unresectable or metastatic melanoma with a BRAF V600E or V600K mutation when used in combination with vemurafenib.
May be explored for use in other cancers with similar genetic mutations, depending on ongoing clinical research and trials.
Key Ingredient
Cobimetinib
Key Benefits
Specifically targets cancer cells with mutations in the MAPK/ERK pathway, potentially leading to better treatment outcomes.
When used with vemurafenib, it can provide a more comprehensive approach to treating melanoma with specific genetic profiles.
Direction of Use
Typically administered as an oral tablet, taken once daily for 21 days followed by a 7-day break, as part of a cycle. The specific dosage and schedule should be tailored to individual patient needs based on medical advice.
Take the tablets with or without food, and follow the prescribed dosing schedule carefully.
Recommended Dose Reductions for COTELLIC:
First Dose Reduction
40 mg orally once daily
Second Dose Reduction
20 mg orally once daily
Subsequent Modification
Permanently discontinue COTELLIC if unable to tolerate 20 mg orally once daily
Safety Concerns
May include diarrhea, nausea, vomiting, rash, and elevated liver enzymes.
Can include severe skin reactions, liver toxicity, heart problems, and eye issues. Regular monitoring by a healthcare provider is essential.
Cotellic may interact with other medications, so inform your healthcare provider of all drugs and supplements you are taking.
Avoid Cotellic (Cobimetinib) If
You have a known hypersensitivity or allergy to cobimetinib or any other component of the medication.
Not recommended for use during pregnancy or breastfeeding due to potential risks to the developing fetus or nursing infant.
Use with caution or avoid if you have severe liver impairment, as cobimetinib can affect liver function.
Caution is needed if you have a history of certain heart conditions, eye disorders, or severe skin reactions.
